Partnership will expand Firefly’s FDA Cleared BNATM technology to more hospitals and physician offices
TORONTO, On., September 10, 2024 – Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a strategic partnership with Zeto, Inc. (“Zeto”), a leading innovator in EEG brain monitoring technology. Under the agreement, Firefly will act as a non-exclusive distributor of Zeto’s FDA-cleared EEG headset devices, cloud platform and services, expanding Firefly’s accessibility to healthcare providers and institutions. This collaboration will also integrate Firefly’s proprietary Brain Network Analytics (BNATM) technology with Zeto’s advanced EEG platform, which is currently being used in more than 200 hospitals and neurology offices across the country.
"This collaboration of two progressive technology companies represents a major step forward in addressing an unmet medical need in brain health," said Jon Olsen, CEO of Firefly. "By combining Zeto’s innovative hardware with our proprietary BNATM technology, this partnership will offer healthcare providers deeper insights into neurological conditions that will ultimately improve patient outcomes.”
Zeto’s EEG headsets — WR19 and Zeto ONE — are FDA-cleared, full-montage, and easy to use, making brain monitoring accessible across various clinical settings, including the ICU, ED, hospital, office, and home. Supported by a robust cloud-based platform, Zeto offers nationwide monitoring and interpretation services by neurologists, along with AI-powered seizure detection and video capabilities. As part of the distribution agreement, Firefly will offer Zeto’s devices and cloud services to its customers, allowing healthcare professionals to access, analyze, and store EEG data in real-time. The integration with Firefly’s BNATM platform enables more precise analysis and expanded use of EEG technology, optimizing diagnostics for a wide range of neurological disorders.
Zeto’s Founder and CEO, Aswin Gunasekar stated, “We are excited to partner with Firefly to offer customers more valuable tools, helping expand our user base and improving the value of EEG. By integrating Firefly’s BNATM offering with Zeto’s EEG platform, we are able to advance our mission of positively impacting patients' lives through transformative, user-friendly, and best-in-class solutions.”
For more information on this partnership and the services offered, please visit: https://fireflyneuro.com/.
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome. Please visit https://fireflyneuro.com/ for more information.
